查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496003

吸药辅助器市场 – 2024 年至 2029 年预测

Asthma Spacers Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

吸药辅助器市场预计将以 4.84% 的复合年增长率成长，到 2029 年达到 2,698,043,000 美元。

吸药辅助器是连接到气喘药物分配机（通常称为吸入器）的容纳室，以促进缓慢有效的药物吸入。气喘吸入器将药物转化为气体形式并将其输送到患者的肺部，从而打开气道。然而，吸入器的口腔空间狭窄，迫使药物进入气道，导致难以吸入，甚至浪费。

储雾器是一根长管，连接到吸入器上，允许患者缓慢吸入药物，减少浪费并更好地吸入。由于污染加剧和慢性病数量增加，预计气喘患者数量增加将在预测期内推动市场成长。气喘病例数量的不断增加，尤其是儿童，他们发现很难直接从吸入器中吸入，预计将推动市场需求。

市场驱动因素：

  • 气喘患者气喘的增加，特别是儿童的增加，增加了气喘吸入器和储雾器的关注和市场引入。

由于需要专门护理、发病早、认识和气喘治疗的进步等因素，气喘，尤其是儿童气喘，越来越受欢迎。建议使用气喘吸入器和储雾器以确保适当的药物输送和治疗效果。由于对气喘症状的认识提高和早期诊断，越来越多的人寻求医疗协助。气喘管理和患者教育计划的进步推动了这一趋势。

气喘是一种广泛存在的慢性呼吸道疾病，会影响气道，由于气道狭窄和肿胀而导致呼吸困难。预计推动吸药辅助器市场成长的主要原因之一是全球气喘病例数量不断增加，尤其是儿童。根据亚太过敏、气喘和临床免疫学协会（PACI）的资料，全球整体有超过30亿人患有气喘。

根据世界卫生组织（WHO）资料库，2019 年有 461,000 人死于该疾病。由于家族遗传和空气污染加剧导致气喘病例增加，预计将增加气喘吸入器和储雾器的采用，推动预测期内的市场成长。

  • 临床对吸入疗法的接受度不断提高，推动了对吸药辅助器的需求。

由于药物传输增强、技术改进、副作用减少、儿科和老年患者易于使用以及吸入药物的全身吸收减少，吸药辅助器市场正在成长。这些设备帮助患者克服协调和时间安排方面的挑战，从而获得更好的临床结果。它还可以减少口腔和喉咙中的药物沉积，从而最大限度地减少潜在的副作用。

Spacer 的使用者友善介面使这些人更容易获得处方药物并提高患者的依从性。垫片还可以减少全身吸收，并有助于将更高比例的药物引导至肺部。它还可以增加肺部的药物沉积并改善气喘控制。病患教育和训练计画也在增加，支持使用垫片的临床证据也在增加。

智慧吸入器技术与储雾器的融合进一步增强了其吸引力。吸药辅助器符合全球改善气喘控制的努力，有助于市场成长。

市场限制因素

  • 用于降低整体药物成本的无间隔技术的市场开拓正在限制吸药辅助器市场的成长。

限制吸药辅助器市场成长的是世界卫生组织建议使用自製替代品和无间隔物技术来降低药物总成本。世卫组织的目标是根据其预防和控制非传染性疾病全球行动计画（2030）减少全世界的气喘。

根据世界卫生组织的一项调查，只有五分之一的气喘患者使用吸入器，大多数人不知道储雾器的使用和重要性。世卫组织在其指导方针和宣传计划中提倡使用宝特瓶製作和使用自製垫片。自製间隔器的低廉价格，加上高昂的治疗和药物成本，鼓励了DIY间隔器的采用，特别是在低收入国家，从而限制了前景广阔的市场机会。

  • 不需要使用间隔器吸入的产品的成长可能会阻碍吸药辅助器市场。

不需要吸入垫片的技术的开拓和新产品的推出对吸药辅助器构成了重大的市场威胁。例如，梯瓦製药公司已成功配製出一种无间隔物气喘药物，可改善患者的呼吸。 QVAR® RediHaler(TM) 是一项 FDA核准的无间隔技术，可像其前身一样有效地输送药物。 QVAR(R) RediHaler(TM) 是围绕呼吸驱动吸入器技术开发的，适合 4 岁以上的患者，甚至儿童也可以在没有储雾器的情况下使用。此类技术的兴起预计将阻碍吸药辅助器行业的市场。

主要进展

  • 2023 年 11 月 - Monaghan Medical Corporation 荣获美国呼吸照护协会 (AARC) 颁发的 2023 年最高奖项。该奖项旨在表彰杰出的产品、友好的销售人员、应对力、服务历史、广告的真实性以及对呼吸护理专业坚定不移的支持。该奖项在田纳西州纳许维尔举行的 AARC 第 67 届国际呼吸大会暨展览会上颁发，表彰了 Monaghan Medical 对卓越呼吸护理的承诺。
  • 2023 年 3 月 - GSK plc 已接受 Nucala（美泊利单抗）的新药认证申请，作为严重嗜酸性粒细胞气喘(SEA) 的附加维持治疗。如果核准，Nucala将成为中国首个针对成人和青少年SEA患者的拮抗介白素-5（IL-5）标靶治疗。本申请基于中国患者的 III 期临床试验和全球 SEA 开发计划的积极资料。中国气喘的成人人数估计为4600万，其中6%患有严重气喘。 Nucala 目前在中国核准用于治疗嗜酸性粒细胞肉芽肿性多血管炎成人患者。

主要市场区隔

依产品类型

  • AeroChamber
  • OpticChamber
  • Easivent
  • 其他的

按分销管道

  • 在线的
  • 离线

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 其他的
  • 中东/非洲 阿联酋 沙乌地阿拉伯 其他中东/非洲
  • UAE
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章吸药辅助器市场：依产品类型

  • 介绍
  • 航空室
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 视室
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 容易发洩
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章吸药辅助器市场：依通路

  • 介绍
  • 在线的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 离线
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章吸药辅助器市场：依地区

  • 介绍
  • 北美洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 按分销管道
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 按分销管道
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞赛仪表板

第九章 公司简介

  • Zydus Cadila
  • Pari Gmbh
  • Cipla
  • Glaxo SmithKline Pharmaceuticals Ltd
  • Rossmax International Ltd.
  • Lupin
简介目录
Product Code: KSI061611950

The asthma spacers market is expected to reach a value of US$2,698.043 million by 2029, growing at a CAGR of 4.84% It was valued at US$1,937.567 million in 2022.

An asthma spacer is a holding chamber attached to an asthma medicine dispensing machine, commonly known as an inhaler, facilitating slower and more effective inhalation of the medicine. An asthma inhaler converts the medicine into gas form and delivers it to the patient's lungs, opening the airways. However, the inhaler has less mouth space and rushes the medicine into the person's airways, making it hard to inhale the medicine and even leading to wastage.

A spacer is attached to the inhaler, a long tube that enables patients to slowly inhale the medicine, reducing wastage and enabling better inhalation. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the market growth during the forecasted period. Rising cases of asthma, especially among children, are expected to drive the market demand since children find it difficult to inhale through the inhaler directly.

Market Drivers:

  • Growing cases of asthma, especially among children, have raised concerns and increased market adoption of asthma inhalers and spacers.

Asthma, particularly among children, is gaining popularity due to factors such as the need for specialized care, early onset, awareness, and advancements in asthma management. Asthma inhalers and spacers are recommended to ensure proper medication delivery and treatment efficacy. The growing awareness of asthma symptoms and early diagnosis has led to more individuals seeking medical attention. Advancements in asthma management and patient education programs are contributing factors to this trend.

Asthma is a widely prevalent respiratory chronic disease that affects the airways, making it difficult for the person to breathe owing to narrowed and/ or swollen up airways. One of the prime reasons expected to drive the asthma spacers market growth is the increasing cases of asthma worldwide, especially among children. Data from the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (PACI) shows that globally, more than 3 billion people suffer from asthma.

The World Health Organization (WHO) database shows that 461,000 people died because of this disease in 2019. Increasing cases of asthma owing to family genetics and rising air pollution are expected to increase the adoption of asthma inhalers and spacers, driving the market growth during the forecast period.

  • Increasing clinical acceptance of inhaled therapies is driving up demand for asthma spacers.

The asthma spacers market is growing due to the enhanced medication delivery, improved technique, reduced side effects, ease of use for children and elderly patients, and reduced systemic absorption of inhaled medications. These devices help patients overcome challenges related to coordination and timing, leading to better clinical outcomes. They also help reduce the deposition of medication in the mouth and throat, minimizing potential side effects.

The user-friendly interface of spacers makes it easier for these populations to receive their prescribed medications, improving patient compliance. Spacers also help reduce systemic absorption, directing a higher proportion of the drug to the lungs. They also increase medication deposition in the lungs, enhancing asthma control. Patient education and training programs are also growing, and clinical evidence supporting spacer use is growing.

The integration of smart inhaler technologies with spacers further enhances their appeal. Asthma spacers align with global efforts for better asthma control, contributing to market growth.

Market Restraints

  • The development of spacer-free technology to reduce the overall cost of medication constraints the market growth of asthma spacers.

The WHO recommends using homemade replacements and spacer-free technology to lower the overall cost of medication, which is what is limiting the market growth of asthma spacers. The WHO aims to reduce global asthma under its Global Action Plan for the Prevention and Control of NCDs, 2030.

A study by the organization observed that only 1/5th of patients suffering from asthma have access to inhalers, and the majority were not aware of the usage and importance of spacers. In its guidelines and awareness programs, WHO promoted the making and usage of homemade spacers using plastic bottles, which could be substituted for branded asthma spacers. The low cost of homemade spacers, accompanied by high treatment and medication costs, encourages the adoption of DIY spacers, especially in low-income countries, and hence constraints the prospective opportunity for the market.

  • Growth of products that do not need to be inhaled with spacers could hinder the asthma spacers market.

The development of technology and the launch of new products that do not require a spacer for inhalation pose a significant market threat for asthma spacers. Teva Pharmaceuticals. for instance, has successfully formulated spacer-free asthma medication, which enables better breathing for the patients. QVAR(R) RediHaler(TM) is an FDA-approved spacer-free technology that delivers medication as effectively as its predecessor. QVAR(R) RediHaler(TM) has been developed around breath-actuated inhaler technology and is apt for four-year-old and older patients, which can be used without the spacer, even for children. The rise in such technology is expected to hinder the market for the asthma spacer industry.

Key Developments:

  • November 2023- Monaghan Medical Corporation was awarded the 2023 Zenith Award by the American Association for Respiratory Care (AARC). The award is prestigious for its exceptional products, accessible sales staff, responsiveness, service record, truth in advertising, and unwavering support of the respiratory care profession. The award was presented at the AARC's 67th International Respiratory Convention & Exhibition in Nashville, Tennessee, highlighting Monaghan Medical's commitment to excellence in respiratory care.
  • March 2023- GSK plc accepted a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA). If approved, Nucala would be the first targeted anti-interleukin-5 (IL-5) treatment in China for adult and adolescent patients with SEA. The application is based on positive data from a phase III trial among Chinese patients and the global SEA development program. Asthma affects an estimated 46 million adults in China, with 6% experiencing severe asthma. Nucala is currently approved in China for adults with eosinophilic granulomatosis with polyangiitis.

Key Market Segments

By Product Type

  • AeroChamber
  • OpticChamber
  • Easivent
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.1. Analyst View

5. ASTHMA SPACERS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. AeroChamber
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. OpticChamber
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Easivent
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. ASTHMA SPACERS MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Online
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Offline
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. ASTHMA SPACERS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Distribution Channel
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. Spain
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. France
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. UAE
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Saudi Arabia
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. Japan
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. China
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Zydus Cadila
  • 9.2. Pari Gmbh
  • 9.3. Cipla
  • 9.4. Glaxo SmithKline Pharmaceuticals Ltd
  • 9.5. Rossmax International Ltd.
  • 9.6. Lupin